- Hello Heart, a rapidly growing heart health digital therapeutics solution, announced that it raised $45 million in Series C funding led by IVP. These are the details.
Hello Heart — a rapidly growing heart health digital therapeutics solution — announced recently that it raised a $45 million Series C round of funding led by IVP. And Hello Heart’s existing investors including Khosla Ventures, BlueRun Ventures, Maven Ventures, and Resolute Ventures also participated in the round. In connection with the funding round, IVP General Partner Somesh Dash will join Hello Heart’s Board of Directors.
Hello Heart is on a mission to empower people to manage and improve their heart health using digital technology. And the company’s flagship solution helps people manage their blood pressure, pulse, medications, and activity using AI-based technology.
Users are able to track key health metrics, receive personalized feedback, and take steps to improve their health with clinically proven suggestions — all through the convenience of their smartphone. And Hello Heart’s solution enables users to quickly identify a hypertensive crisis or irregular heartbeat, facilitating a timely referral to their doctor to treat and prevent a potentially catastrophic cardiac event.
The company tripled its business over the last year, with its program being offered by large enterprise companies, including many Fortune 500 employers as part of their benefits programs. And Hello Heart is the only digital therapeutic hypertension solution with a peer-reviewed clinical study on blood pressure outcomes. Plus it has been recognized for hypertension management by the American Heart Association. And after a thorough clinical and security review, CVS Health added Hello Heart to its prestigious Point Solutions Management platform.
In a retrospective peer-reviewed study performed by researchers at UCLA and Harvard Medical School, 70% of users reduced their blood pressure and the average decrease of systolic blood pressure was 22 mmHg. And these clinical results are over 2x higher than any other results published in a peer-reviewed clinical study. Dr. Eyal Zimlichman, Harvard Medical School Faculty Research associate and Chief Medical Officer of Sheba Medical Center, led this research.
KEY QUOTES:
“Our mission is to empower people to understand and improve their health using technology, and we’re very proud to help them do it effectively in heart health – the #1 cause of death in the world. We’re in an exciting growth phase and this investment will allow us to rapidly scale our teams and technology, continuing to build on our leadership position in digital therapeutics for cardiovascular disease.”
— Maayan Cohen, CEO of Hello Heart
“Whether you’re dealing with a preexisting health condition or consider yourself healthy, Hello Heart’s offering can truly save your life. The market for heart disease is large and adoption of digital solutions is accelerating quickly. Hello Heart has an opportunity to become the digital therapeutics leader for all cardiovascular diseases and we’re excited to partner with them on their growth phase.”
— Somesh Dash, General Partner at IVP
“Hypertension is the most prevalent chronic condition in America, impacting roughly half the US population. Given the opportunity to improve millions of lives and save billions of dollars in healthcare spend, we couldn’t be more thrilled to support the Hello Heart team on the road ahead.”
— Parsa Saljoughian, Partner at IVP
“Delivering clinical outcomes at the scale of population health requires strong patient engagement across a variety of patient types. Hello Heart’s ability to drive engagement is what led to these unprecedented results.”
— Dr. Eyal Zimlichman
